Literature DB >> 17240000

Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.

Cassandra M James1, Mohammad Y Abdad, Josephine P Mansfield, Hege K Jacobsen, Azita Rezazadeh Vind, Philip A Stumbles, Emmalene J Bartlett.   

Abstract

Vaccines are urgently needed to elicit immunity to different influenza virus strains. DNA vaccines can elicit partial protective immunity, however their efficacy requires improvement. We assessed the capacity of individual type I IFN multigene family members as subtype transgenes to abrogate influenza virus replication in a vaccination/challenge mouse model. Differences in antiviral efficacy were found among the subtypes with IFNA5 and IFNA6 being most effective, while IFNA1 was the least effective in reducing lung virus replication. Mice vaccinated with combinatorial HA/IFNA6 or NP/IFNA6 showed reduced lung viral titres, clinical score, body weight loss, and pulmonary tissue damage compared to IFNA6, HA, or NP viral vaccination alone. In addition, IFNA6 increased IgG2a titres with upregulation of IFN-gamma response in the respiratory tract. We conclude that IFN-alpha 6 has antiviral and immunomodulatory effects, which improve efficacy of DNA vaccines for enhanced control of influenza.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17240000     DOI: 10.1016/j.vaccine.2006.10.038

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

2.  The early interferon alpha subtype response in infant macaques infected orally with SIV.

Authors:  Juliet Easlick; Richard Szubin; Samantha Lantz; Nicole Baumgarth; Kristina Abel
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

3.  A DNA vaccine-encoded nucleoprotein of influenza virus fails to induce cellular immune responses in a diabetic mouse model.

Authors:  Abbas Jamali; Farzaneh Sabahi; Taravat Bamdad; Hamidreza Hashemi; Fereidoun Mahboudi; Masume Tavasoti Kheiri
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

Review 4.  IFN-α subtypes: distinct biological activities in anti-viral therapy.

Authors:  K Gibbert; J F Schlaak; D Yang; U Dittmer
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

5.  The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.

Authors:  Kenneth W Hance; Connie J Rogers; David A Zaharoff; Daniel Canter; Jeffrey Schlom; John W Greiner
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

6.  Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.

Authors:  Kerry J Lavender; Kathrin Gibbert; Karin E Peterson; Erik Van Dis; Sandra Francois; Tyson Woods; Ronald J Messer; Ali Gawanbacht; Janis A Müller; Jan Münch; Katie Phillips; Brent Race; Michael S Harper; Kejun Guo; Eric J Lee; Mirko Trilling; Hartmut Hengel; Jacob Piehler; Jens Verheyen; Cara C Wilson; Mario L Santiago; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

7.  IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection.

Authors:  Lianna Li; Barbara Sherry
Journal:  Virology       Date:  2009-11-06       Impact factor: 3.616

8.  Internal ribosome entry site-based attenuation of a flavivirus candidate vaccine and evaluation of the effect of beta interferon coexpression on vaccine properties.

Authors:  Michael Frese; Eva Lee; Maximilian Larena; Pek Siew Lim; Sudha Rao; Klaus I Matthaei; Alexander Khromykh; Ian Ramshaw; Mario Lobigs
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

Review 9.  Potential role of IFN-α in COVID-19 patients and its underlying treatment options.

Authors:  Lei Yang; Jianhui Wang; Pei Hui; Timur O Yarovinsky; Saiaditya Badeti; Kien Pham; Chen Liu
Journal:  Appl Microbiol Biotechnol       Date:  2021-05-05       Impact factor: 4.813

10.  Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Authors:  Elizabeth B Norton; John D Clements; Thomas G Voss; Lucia Cárdenas-Freytag
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.